HUTCHMED provides full year 2025 guidance for Oncology/Immunology consolidated revenue of $350 million to $450 million. HUTCHMED's work in 2025 and beyond will be supported by its strong balance sheet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback